Hims & Hers Health, Inc.

Valuation Analysis

About the Company

Hims & Hers Health, Inc. en bref

Hims & Hers Health, Inc. (HIMS) is currently trading at 30,92 € with a market capitalization of 7,2 Md €. The 52-week range spans from 11,98 € to 61,40 €; the current price is 49.6% below the yearly high. Year-over-year revenue growth stands at +3.8%.

💰 Dividende

Hims & Hers Health, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

14 analystes évaluent Hims & Hers Health, Inc. (HIMS) au consensus : Conserver. L'objectif de cours moyen est de 23,20 €, soit un potentiel de -24.99% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 18,31 € à 30,51 €.

Hims & Hers Health, Inc. : la thèse d'investissement en détail

Hims & Hers Health, Inc. (HIMS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 72.92%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Revenue growth has slowed to just 3.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 253.72% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

The EV/EBITDA multiple of 91.89x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (32.57%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Hims & Hers Health, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.